PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Entrectinib→

Entrectinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1108743-60-7
Molecular formula
C31H34F2N6O2
Molecular weight
560.64 g/mol
Drug class
TRK/ROS1/ALK tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Inhibits TRKA, TRKB and TRKC, ROS1 and ALK kinase activity, suppressing oncogenic signalling in tumours driven by NTRK gene fusions or ROS1 rearrangements.
Indications / reported uses
  • Treatment of adults and paediatric patients with solid tumours harbouring an NTRK gene fusion, when disease is metastatic or surgery is likely to cause severe morbidity and there is no satisfactory alternative therapy or progression following treatment
  • Treatment of adults with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) under the applicable product label

Sources: US DailyMed — ROZLYTREK (entrectinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Entrectinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Entrectinib Permitted Daily Exposure (PDE) report (the Entrectinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Entrectinib Occupational Exposure Limit (OEL) report (the Entrectinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.